Back to News
Market Impact: 0.05
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
Source: PR Newswire
Healthcare & Biotech
The provided excerpt only identifies Innovent Biologics as a biopharmaceutical company focused on innovative therapies for major diseases, including oncology. It contains no substantive clinical, regulatory, financial, product, or corporate-development announcement to assess.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Here are the 4 big things we're watching in the stock market in the week ahead
- OpenAI, Anthropic CEOs called to appear at Australian AI probe
- Australia summons OpenAI and Anthropic CEOs to appear at AI inquiry
- TechCrunch Mobility: AV companies pick their lanes
- Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution
- 3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Selecting an AI Research Platform for Institutional Investors
- Weekly Update: New Reporting Features and More Sources for Document Search